Nevertheless, clinical trials are underway to investigate the effectiveness of M7824—a fusion protein consisting of a human IgG1 monoclonal antibody against PD-L1 fused to the extracellular domain of the receptor for TGF-β, which captures TGF-β in the tumour environment [86]. This evidence concerns the gene TGFB1 and neoplasm.